This article presents the design and rationale of the TACT2 trial, a randomized, double-blind, placebo-controlled study aiming to confirm the cardiovascular benefits of EDTA chelation therapy observed in diabetic patients in the original TACT trial. Targeting a high-risk population of 1,200 patients with diabetes and prior myocardial infarction, the trial
